Cedars-sinai Medical Center

Prometheus Biosciences, Inc.

Dr. Falk Pharma Gmbh

Dermot P Mcgovern

Janine M Bilsborough

Dalin Li

Stephan R Targan

Jeffry Dean Watkins

Jerome I Rotter

Kent D Taylor

Marla C Dubinsky

Laurens Kruidenier

Mahyar Sabripour

Janine Bilsborough

Cindy T Dickerson

Talin Haritunians

Alka Potdar

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease

Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohns disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.

Methods and systems for selection and treatment of patients with inflammatory diseases

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNF SF15 (or TL1A) and/or DcR3 genetic loci.

Variants of TNFSF15 and DCR3 associated with Crohn's disease

Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods. kits and compositions may be particularly useful for subjects carrying a risk genotype and/or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.

Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures

Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody

The present invention describes a method of prognosing high or low probability of developing an inflammatory bowel disease (IBD) in a subject and a method of diagnosing an inflammatory bowel disease (IBD) in a subject. The invention further provides for a method of identifying genes/genetic loci associated with a disease condition, such as IBD, CD and/or UC.

Diagnosis of inflammatory bowel disease based on genes

Growing community of inventors

Los Angeles, CA, United States of America

Dermot P Mcgovern